Inhibition of ovulation by administration of estetrol in combination with drospirenone or levonorgestrel: Results of a phase II dose-finding pilot study
暂无分享,去创建一个
J. Foidart | H. C. Coelingh Bennink | C. Klipping | C. Maillard | M. Jost | M. Mawet | Y. Zimmerman | N. Appels | I. Duijkers | Catherine Maillard
[1] S. Steurer,et al. Antiestrogenic effects of the fetal estrogen estetrol in women with estrogen-receptor positive early breast cancer. , 2014, Carcinogenesis.
[2] J. Foidart,et al. Estetrol is a weak estrogen antagonizing estradiol-dependent mammary gland proliferation. , 2014, The Journal of endocrinology.
[3] Sung Hoon Kim,et al. Mutation of the palmitoylation site of estrogen receptor α in vivo reveals tissue-specific roles for membrane versus nuclear actions , 2013, Proceedings of the National Academy of Sciences.
[4] F. Lenfant,et al. The AF-1 activation function of estrogen receptor alpha is necessary and sufficient for uterine epithelial cell proliferation in vivo , 2013 .
[5] F. Lenfant,et al. The AF-1 activation function of estrogen receptor α is necessary and sufficient for uterine epithelial cell proliferation in vivo. , 2013, Endocrinology.
[6] Niels Keiding,et al. Thrombotic stroke and myocardial infarction with hormonal contraception. , 2012, The New England journal of medicine.
[7] H. Kloosterboer,et al. Estetrol prevents and suppresses mammary tumors induced by DMBA in a rat model , 2012, Hormone molecular biology and clinical investigation.
[8] E. Løkkegaard,et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9 , 2011, BMJ : British Medical Journal.
[9] C. Klipping,et al. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol on ovarian function in comparison to a monophasic combined oral contraceptive containing drospirenone and ethinylestradiol , 2010, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.
[10] P. Reitsma,et al. 17α‐Ethinylestradiol rapidly alters transcript levels of murine coagulation genes via estrogen receptor α , 2010, Journal of thrombosis and haemostasis : JTH.
[11] J. Endrikat,et al. Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies. , 2008, Contraception.
[12] C. Klipping,et al. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. , 2008, Contraception.
[13] H. C. Coelingh Bennink,et al. Ovulation inhibition by estetrol in an in vivo model. , 2008, Contraception.
[14] E. Diczfalusy,et al. Estetrol review: profile and potential clinical applications , 2008, Climacteric : the journal of the International Menopause Society.
[15] J. Foidart,et al. In vitro effects of estetrol on receptor binding, drug targets and human liver cell metabolism , 2008, Climacteric : the journal of the International Menopause Society.
[16] H. C. Coelingh Bennink,et al. First human exposure to exogenous single-dose oral estetrol in early postmenopausal women , 2008, Climacteric : the journal of the International Menopause Society.
[17] H. C. Coelingh Bennink,et al. Ovulation inhibition by estetrol in an in vivo model , 2008, Climacteric : the journal of the International Menopause Society.
[18] C. Verhoeven,et al. Ovarian function with the contraceptive vaginal ring or an oral contraceptive: a randomized study. , 2004, Human reproduction.
[19] C. Gerlinger,et al. A meta-analysis on the correlation between ovarian activity and the incidence of intermenstrual bleeding during low-dose oral contraceptive use , 2003, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.
[20] J. Barrett,et al. The ability of four catechol estrogens of 17beta-estradiol and estrone to induce DNA adducts in Syrian hamster embryo fibroblasts. , 2001, Carcinogenesis.
[21] P. Coney,et al. The effects on ovarian activity of a monophasic oral contraceptive with 100 μg levonorgestrel and 20 μg ethinyl estradiol , 1999 .
[22] W. Rossmanith,et al. A comparative randomized trial on the impact of two low-dose oral contraceptives on ovarian activity, cervical permeability, and endometrial receptivity. , 1997, Contraception.
[23] T. Rabe,et al. The effects of monophasic and triphasic oral contraceptives on ovarian function and endometrial thickness. , 1997, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.
[24] W. Feichtinger,et al. A comparison of the effects of two monophasic low dose oral contraceptives on the inhibition of ovulation , 1994, Advances in contraception : the official journal of the Society for the Advancement of Contraception.
[25] P. Knipschild,et al. Oral contraceptives and the risk of gallbladder disease: a meta-analysis. , 1993, American journal of public health.
[26] H. Hoogland,et al. Ultrasound evaluation of ovarian activity under oral contraceptives. , 1993, Contraception.
[27] K. Thomas,et al. Inhibition of ovulation by low-dose monophasic contraceptive containing gestodene. , 1990, American journal of obstetrics and gynecology.
[28] E. Diczfalusy,et al. METABOLISM OF 17β-OESTRADIOL-4-14C IN EARLY INFANCY , 1965 .
[29] D. Grimes,et al. The European Journal of Contraception and Reproductive Health Care , 2002 .
[30] P. Coney,et al. The effects on ovarian activity of a monophasic oral contraceptive with 100 microg levonorgestrel and 20 microg ethinyl estradiol. , 1999, American journal of obstetrics and gynecology.
[31] H. Feenstra,et al. Endocrinological studies with (7 alpha, 17 alpha)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one (Org OD 14). , 1984, Arzneimittel-Forschung.
[32] H. Behre,et al. Reproduktionsmedizin und Endokrinologie , 2022 .